Literature DB >> 6832208

The absolute bioavailability of caffeine in man.

J Blanchard, S J Sawers.   

Abstract

The absolute bioavailability of orally administered caffeine was investigated in 10 healthy adult male volunteers, aged 18.8 to 30.0 years. The subjects were administered a 5 mg/kg dose of caffeine as either an aqueous oral solution or an intravenous infusion, on separate occasions about 1 week apart, in a randomized crossover fashion. Plasma samples were collected over the 24-h period following each dose and assayed for their caffeine content using a high-performance liquid chromatographic technique. The oral absorption was very rapid, reaching a peak (Tp) plasma concentration after 29.8 +/- 8.1 min (mean +/- SEM). In addition, the variation in the maximum plasma concentration (Cmax) was low, 10.0 +/- 1.0 micrograms/ml. The absolute bioavailability was assessed by comparing the areas under the plasma concentration vs. time curves for the intravenous and oral doses of caffeine. The rapid absorption resulted in essentially complete bioavailability of the oral caffeine, F(%) = 108.3 +/- 3.6%. The caffeine plasma half-lives varied from 2.7 to 9.9 h, indicating substantial inter-subject variability in its elimination.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832208     DOI: 10.1007/bf00613933

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  The fate of caffeine in man and a method for its estimation in biological material.

Authors:  J AXELROD; J REICHENTHAL
Journal:  J Pharmacol Exp Ther       Date:  1953-04       Impact factor: 4.030

2.  Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene.

Authors:  A Aldridge; W D Parsons; A H Neims
Journal:  Life Sci       Date:  1977-10-01       Impact factor: 5.037

3.  Interconversion of theophylline and caffeine in newborn infants.

Authors:  H S Bada; N N Khanna; S M Somani; A A Tin
Journal:  J Pediatr       Date:  1979-06       Impact factor: 4.406

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Normalization in the fitting of data by iterative methods. Application to tracer kinetics and enzyme kinetics.

Authors:  J H Ottaway
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

6.  Elimination of a potential interference in assay for plasma caffeine.

Authors:  J Blanchard; J D Mohammadi; J M Trang
Journal:  Clin Chem       Date:  1981-04       Impact factor: 8.327

7.  Plasma area method in relative bioavailability evaluation of drugs with changing biological half-lives.

Authors:  W L Chiou; C Y Lui; G Lam
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

8.  Improved liquid-chromatographic determination of caffeine in plasma.

Authors:  J Blanchard; J D Mohammadi; K A Conrad
Journal:  Clin Chem       Date:  1980-08       Impact factor: 8.327

9.  Efficacy of caffeine in treatment of apnea in the low-birth-weight infant.

Authors:  J V Aranda; W Gorman; H Bergsteinsson; T Gunn
Journal:  J Pediatr       Date:  1977-03       Impact factor: 4.406

10.  Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.

Authors:  J V Aranda; C E Cook; W Gorman; J M Collinge; P M Loughnan; E W Outerbridge; A Aldridge; A H Neims
Journal:  J Pediatr       Date:  1979-04       Impact factor: 4.406

  10 in total
  71 in total

Review 1.  The impact of caffeine on vasodilator stress perfusion studies.

Authors:  Andre C Lapeyre; Tauqir Y Goraya; Donald L Johnston; Raymond J Gibbons
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

2.  Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Authors:  David R Plowchalk; Karen Rowland Yeo
Journal:  Eur J Clin Pharmacol       Date:  2012-01-19       Impact factor: 2.953

Review 3.  Energy beverages: content and safety.

Authors:  John P Higgins; Troy D Tuttle; Christopher L Higgins
Journal:  Mayo Clin Proc       Date:  2010-11       Impact factor: 7.616

4.  Effects of moderate exercise on the pharmacokinetics of caffeine.

Authors:  K Collomp; F Anselme; M Audran; J P Gay; J L Chanal; C Prefaut
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Rapid and sensitive gas-chromatographic determination of caffeine in blood plasma, saliva, and xanthine beverages.

Authors:  H W Teeuwen; E L Elbers; J M van Rossum
Journal:  Mol Biol Rep       Date:  1991-02       Impact factor: 2.316

Review 6.  Practicing safe SPECT: caffeine abstinence in nuclear myocardial perfusion imaging.

Authors:  Kristina E Powles; Renee C Hessian; Terrence D Ruddy
Journal:  J Nucl Cardiol       Date:  2008 Sep-Oct       Impact factor: 5.952

7.  Reproducibility of pharmacological ASL using sequences from different vendors: implications for multicenter drug studies.

Authors:  Henri J M M Mutsaerts; Rebecca M E Steketee; Dennis F R Heijtel; Joost P A Kuijer; Matthijs J P van Osch; Charles B L M Majoie; Marion Smits; Aart J Nederveen
Journal:  MAGMA       Date:  2015-01-15       Impact factor: 2.310

Review 8.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 9.  Caffeine as an attention enhancer: reviewing existing assumptions.

Authors:  Suzanne J L Einöther; Timo Giesbrecht
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

10.  Interaction between oral ciprofloxacin and caffeine in normal volunteers.

Authors:  D P Healy; R E Polk; L Kanawati; D T Rock; M L Mooney
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.